Developer docs
API playgroundTry for free, no card

Search company profiles

Agendia

Full company profile

uuid0002575

Namestring
Agendia
Legal namestring
Agendia, Inc.
Websiteurl
agendia.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Agendia is a privately held molecular diagnostics company founded in 2003 by Prof. Laura van 't Veer and Prof. René Bernards at the Netherlands Cancer Institute, dual-headquartered in Amsterdam (Netherlands) and Irvine, California (US), with 101–250 employees. The company develops and commercializes genomic tests for early-stage breast cancer, principally the FDA-cleared and CE-marked MammaPrint 70-gene expression profiling test (recurrence risk) and the CE-marked BluePrint 80-gene molecular subtyping test. Both tests are run on microarray and next-generation sequencing technology from a single tumor sample, with results returned within 6 business days; the combined suite analyzes over 150 genes covering all 10 Hallmarks of Cancer and is indicated across Stage I–III disease including node-positive patients.

The company's commercial model is built on direct sales to healthcare providers — oncologists, breast surgeons, and pathologists — who order tests through regional provider portals, email, or fax, with billing handled directly via CMS Medicare and most US commercial health plans plus select European public healthcare systems. Reimbursement covers the one-time per-test fee, and four financial support programs address uninsured patients. Agendia supplements provider-facing GTM with a patient pull-through motion via partnerships with advocacy organizations (Susan G. Komen, Living Beyond Breast Cancer, Tigerlily Foundation, Learn Look Locate, Dandelion Toolkit), educational content, and a breast cancer blog. Over 20+ years, the company has built a deep evidence base including the MINDACT trial (New England Journal of Medicine, 2016), the prospective FLEX Study (20,000+ enrolled of a 30,000-patient goal across 107 sites), 200+ research collaborations, and hundreds of peer-reviewed publications, with multiple ongoing Phase III trials (DEBRA, SWOG S2206, LESS, PROOFS, INSIGHT, I-SPY2) reinforcing clinical guideline inclusion.

Short descriptiontext

Agendia is a privately held molecular diagnostics company that develops and commercializes the FDA-cleared MammaPrint and CE-marked BluePrint genomic tests to help oncologists personalize early-stage breast cancer treatment decisions, serving healthcare providers and patients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breast cancer diagnostics, genomic profiling tests, molecular subtyping, recurrence risk testing, precision oncology
Industry2 codes
PRIMARYHLAKAFAJ
Breast Oncology
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1MammaPrint Test
TypeOne Time License
Description

One-time genomic test for early-stage breast cancer patients that analyzes tumor tissue from core needle biopsy or surgical resection. Results inform treatment decisions including chemotherapy benefit and endocrine therapy planning. Reimbursed by CMS (Medicare) and most commercial health plans in the US.

agendia.com
2BluePrint Test
TypeOne Time License
Description

One-time molecular subtyping test that classifies tumors into molecular subtypes. Performed alongside or independently of MammaPrint. Also reimbursed by Medicare and commercial insurers.

agendia.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Test pricing varies by region and insurance coverage
ModelOtherBilling cadenceOne time
Notes

Cost varies globally based on geographic location, insurance coverage, and individual circumstances. US and Puerto Rico: MammaPrint is reimbursed by CMS (Medicare) and most commercial health plans. Contact local healthcare provider with questions.

agendia.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1MammaPrint
Description

FDA-cleared and CE-marked 70-gene expression profiling test that determines risk of breast cancer recurrence (UltraLow Risk, Low Risk, High Risk 1, High Risk 2). Analyzes the 70 most important genes associated with breast cancer recurrence.

agendia.com
+1 more record
Core offering1 text field

Agendia provides clinical genomic diagnostic testing services for early-stage breast cancer, anchored by its MammaPrint 70-gene recurrence risk test and BluePrint 80-gene molecular subtyping test. Both tests are run from a single tumor tissue sample in Agendia's CLIA-regulated, CAP-accredited laboratories and produce combined results within 6 business days to help oncologists, surgeons, and pathologists personalize treatment decisions including chemotherapy benefit, endocrine therapy planning, and identification of aggressive tumor subtypes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 46% of clinically high-risk patients reclassified as MammaPrint Low Risk and able to forgo chemotherapy without compromising outcomes
+6 more records
Product overview1 text field

Agendia offers a genomic test suite consisting of two FDA-cleared and CE-marked tests for early-stage breast cancer: MammaPrint (70-gene signature) and BluePrint (80-gene signature). Together, these tests analyze over 150 genes from a single tumor sample to provide comprehensive genomic profiling that determines recurrence risk and molecular subtype within 6 business days. The test suite helps physicians personalize treatment decisions including chemotherapy benefit, endocrine therapy duration, and identification of aggressive tumor subtypes.

Product and service3 records
1MammaPrint
CategoryMolecular Diagnostics
Description

FDA-cleared and CE-marked 70-gene expression profiling test that analyzes breast tumor tissue to determine the risk of cancer recurrence, stratifying patients into UltraLow Risk, Low Risk, High Risk 1, and High Risk 2 categories to guide chemotherapy benefit and treatment planning decisions for early-stage breast cancer patients.

2BluePrint
CategoryMolecular Diagnostics
Description

CE-marked 80-gene molecular subtyping test that classifies breast tumors into Luminal-Type, HER2-Type, or Basal-Type molecular subtypes to reveal the underlying biology driving tumor growth and guide personalized treatment planning. Performed exclusively by Agendia in its CLIA-regulated, CAP-accredited laboratory.

3MammaPrint + BluePrint Test Suite
CategoryMolecular Diagnostics
Description

Combined genomic testing from a single tumor block that interrogates over 150 genes containing information on tumor aggression and growth potential, providing both MammaPrint recurrence risk and BluePrint molecular subtype results within 6 business days for early-stage breast cancer treatment planning.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Vanderbilt University Medical Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Research collaboration on genomic testing studies. Researchers at Vanderbilt Health and Agendia co-published study in npj Breast Cancer finding higher prevalence of high-risk breast cancer in Black women. Study analyzed 1,018 women using MammaPrint and BluePrint genomic testing technologies.

news.vumc.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NCI-sponsored SWOG S2206 Phase III trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for MammaPrint High Risk 2 HR+/HER2- breast cancer. NCI-funded network including Alliance, ECOG-ACRIN, and NRG Oncology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sponsor of DEBRA Phase III trial evaluating breast conservation surgery with and without radiation in MammaPrint Low Risk patients. Collaborator with National Cancer Institute.

4UNICANCER
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sponsor of LESS study evaluating de-escalation of adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- breast cancer and MammaPrint Ultra Low Risk. Up to 50 French sites.

agendia.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sponsor of PROOFS Registry study evaluating endocrine therapy in pre- and perimenopausal luminal early breast cancer patients with MammaPrint Low Risk.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborator on INSIGHT Trial evaluating impact of 2nd line chemotherapy on survival in patients with non-Luminal A HR+ metastatic breast cancer using Blueprint and MammaPrint gene expression profiling tests.

7I-SPY2 Trial Network
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Adaptive platform trial employing master framework allowing multiple treatments to be studied in parallel. Agendia contributes genomic profiling to guide treatment evaluation.

agendia.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sponsor of MINDACT Phase III trial demonstrating MammaPrint's ability to safely de-escalate chemotherapy in clinically high-risk, MammaPrint Low Risk early-stage breast cancer patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Owner of the Oncotype DX Breast Recurrence Score test, the leading genomic assay for early-stage breast cancer treatment planning. Most direct competitor to MammaPrint, with broader indication coverage and substantially larger commercial scale.

TypeDirect peer
Description

Developer of the Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50-based), a direct competitor providing breast cancer subtype and recurrence risk classification from FFPE tissue. Competes head-to-head with MammaPrint/BluePrint in the same indication.

TypeBroad incumbent
Description

Genomic diagnostics company spanning multiple indications (urology, thyroid, breast) including Prosigna-related assets and broader oncology decision-support. Larger and more diversified than Agendia, with overlapping breast cancer genomic testing.

TypeBroad incumbent
Description

Established molecular diagnostics company with oncology and women's health testing (including BRACAnalysis and risk-of-recurrence assays). Larger scale and broader indication footprint, with overlapping oncology sales channels and shared leadership pedigree with Agendia (Agendia's CCO previously at Myriad).

TypeEmerging player
Description

Liquid biopsy leader (Guardant360, Guardant Reveal) expanding into breast cancer minimal residual disease and treatment monitoring. Represents the emerging blood-based alternative that could pressure Agendia's tissue-based testing model over time.

TypeBroad incumbent
Description

Oncology-focused clinical laboratory services company offering comprehensive cancer genomic profiling across solid tumors. Serves similar hospital and oncologist customers and overlaps with Agendia on certain oncology biomarker testing.

TypeBroad incumbent
Description

Provider of comprehensive molecular profiling services (MI Profile, Caris Assure) used by oncologists for therapy selection. Comparable in serving oncologists with tumor profiling data, with a much broader indication footprint than Agendia.

8Tempus AI
TypeBroad incumbent
Description

AI-enabled precision medicine platform offering multi-modal molecular profiling (DNA, RNA, imaging) for oncology. Competes for the same oncologist decision-support wallet with broader data and analytics capabilities than Agendia.

TypeEmerging player
Description

Cell-free DNA testing company (Signatera) with growing presence in MRD and breast cancer recurrence monitoring. Represents the emerging blood-based competitive threat to Agendia's tissue-based recurrence risk testing.

TypeBroad incumbent
Description

Women's health diagnostics leader (including breast cancer screening and biopsy systems). Adjacent rather than directly competitive, but operates in the same breast cancer diagnostic workflow and could be a strategic acquirer of genomic testing assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Agendia

Molecular Diagnosticsagendia.com

Agendia is a privately held molecular diagnostics company that develops and commercializes the FDA-cleared MammaPrint and CE-marked BluePrint genomic tests to help oncologists personalize early-stage breast cancer treatment decisions, serving healthcare providers and patients globally.

What Agendia does

Agendia is a privately held molecular diagnostics company founded in 2003 by Prof. Laura van 't Veer and Prof. René Bernards at the Netherlands Cancer Institute, dual-headquartered in Amsterdam (Netherlands) and Irvine, California (US), with 101–250 employees. The company develops and commercializes genomic tests for early-stage breast cancer, principally the FDA-cleared and CE-marked MammaPrint 70-gene expression profiling test (recurrence risk) and the CE-marked BluePrint 80-gene molecular subtyping test. Both tests are run on microarray and next-generation sequencing technology from a single tumor sample, with results returned within 6 business days; the combined suite analyzes over 150 genes covering all 10 Hallmarks of Cancer and is indicated across Stage I–III disease including node-positive patients.

The company's commercial model is built on direct sales to healthcare providers — oncologists, breast surgeons, and pathologists — who order tests through regional provider portals, email, or fax, with billing handled directly via CMS Medicare and most US commercial health plans plus select European public healthcare systems. Reimbursement covers the one-time per-test fee, and four financial support programs address uninsured patients. Agendia supplements provider-facing GTM with a patient pull-through motion via partnerships with advocacy organizations (Susan G. Komen, Living Beyond Breast Cancer, Tigerlily Foundation, Learn Look Locate, Dandelion Toolkit), educational content, and a breast cancer blog. Over 20+ years, the company has built a deep evidence base including the MINDACT trial (New England Journal of Medicine, 2016), the prospective FLEX Study (20,000+ enrolled of a 30,000-patient goal across 107 sites), 200+ research collaborations, and hundreds of peer-reviewed publications, with multiple ongoing Phase III trials (DEBRA, SWOG S2206, LESS, PROOFS, INSIGHT, I-SPY2) reinforcing clinical guideline inclusion.

Agendia firmographics

Firmographics
Name
Agendia
Legal name
Agendia, Inc.
Website
https://agendia.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
Agendia is a privately held molecular diagnostics company that develops and commercializes the FDA-cleared MammaPrint and CE-marked BluePrint genomic tests to help oncologists personalize early-stage breast cancer treatment decisions, serving healthcare providers and patients globally.
Ownership category
akta.pro rank

Agendia industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAKAFAJ
Breast Oncology
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)

Keywords

  • Breast cancer diagnostics
  • Genomic profiling tests
  • Molecular subtyping
  • Recurrence risk testing
  • Precision oncology

Where Agendia is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Agendia business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. MammaPrint Test: One-time genomic test for early-stage breast cancer patients that analyzes tumor tissue from core needle biopsy or surgical resection. Results inform treatment decisions including chemotherapy benefit and endocrine therapy planning. Reimbursed by CMS (Medicare) and most commercial health plans in the US.
  2. BluePrint Test: One-time molecular subtyping test that classifies tumors into molecular subtypes. Performed alongside or independently of MammaPrint. Also reimbursed by Medicare and commercial insurers.

Pricing tiers

ModelBillingPrice
OtherOne timeTest pricing varies by region and insurance coverage

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Agendia product offering

Product offering

Core offering

Agendia provides clinical genomic diagnostic testing services for early-stage breast cancer, anchored by its MammaPrint 70-gene recurrence risk test and BluePrint 80-gene molecular subtyping test. Both tests are run from a single tumor tissue sample in Agendia's CLIA-regulated, CAP-accredited laboratories and produce combined results within 6 business days to help oncologists, surgeons, and pathologists personalize treatment decisions including chemotherapy benefit, endocrine therapy planning, and identification of aggressive tumor subtypes.

Product overview

Agendia offers a genomic test suite consisting of two FDA-cleared and CE-marked tests for early-stage breast cancer: MammaPrint (70-gene signature) and BluePrint (80-gene signature). Together, these tests analyze over 150 genes from a single tumor sample to provide comprehensive genomic profiling that determines recurrence risk and molecular subtype within 6 business days. The test suite helps physicians personalize treatment decisions including chemotherapy benefit, endocrine therapy duration, and identification of aggressive tumor subtypes.

Differentiator

Problem solved

Functional benefit

Brands

  • MammaPrint: FDA-cleared and CE-marked 70-gene expression profiling test that determines risk of breast cancer recurrence (UltraLow Risk, Low Risk, High Risk 1, High Risk 2). Analyzes the 70 most important genes associated with breast cancer recurrence.
  • BluePrint

Products and services

  • MammaPrint FDA-cleared and CE-marked 70-gene expression profiling test that analyzes breast tumor tissue to determine the risk of cancer recurrence, stratifying patients into UltraLow Risk, Low Risk, High Risk 1, and High Risk 2 categories to guide chemotherapy benefit and treatment planning decisions for early-stage breast cancer patients.
  • BluePrint CE-marked 80-gene molecular subtyping test that classifies breast tumors into Luminal-Type, HER2-Type, or Basal-Type molecular subtypes to reveal the underlying biology driving tumor growth and guide personalized treatment planning. Performed exclusively by Agendia in its CLIA-regulated, CAP-accredited laboratory.
  • MammaPrint + BluePrint Test Suite Combined genomic testing from a single tumor block that interrogates over 150 genes containing information on tumor aggression and growth potential, providing both MammaPrint recurrence risk and BluePrint molecular subtype results within 6 business days for early-stage breast cancer treatment planning.

Quantifiable outcome

  • 46% of clinically high-risk patients reclassified as MammaPrint Low Risk and able to forgo chemotherapy without compromising outcomes
  • +6 more outcomes

Companies that use Agendia

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Agendia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Agendia partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • Vanderbilt University Medical CentercoreStrategic or Co-development Partner · 14 April 2026Research collaboration on genomic testing studies. Researchers at Vanderbilt Health and Agendia co-published study in npj Breast Cancer finding higher prevalence of high-risk breast cancer in Black women. Study analyzed 1,018 women using MammaPrint and BluePrint genomic testing technologies.
  • National Cancer Institute (NCI)coreStrategic or Co-development PartnerNCI-sponsored SWOG S2206 Phase III trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for MammaPrint High Risk 2 HR+/HER2- breast cancer. NCI-funded network including Alliance, ECOG-ACRIN, and NRG Oncology.
  • NRG OncologycoreStrategic or Co-development PartnerSponsor of DEBRA Phase III trial evaluating breast conservation surgery with and without radiation in MammaPrint Low Risk patients. Collaborator with National Cancer Institute.
  • UNICANCERcoreStrategic or Co-development PartnerSponsor of LESS study evaluating de-escalation of adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- breast cancer and MammaPrint Ultra Low Risk. Up to 50 French sites.
  • West German Study GroupcoreStrategic or Co-development PartnerSponsor of PROOFS Registry study evaluating endocrine therapy in pre- and perimenopausal luminal early breast cancer patients with MammaPrint Low Risk.
  • Susan G. Komen Breast Cancer FoundationcoreStrategic or Co-development PartnerCollaborator on INSIGHT Trial evaluating impact of 2nd line chemotherapy on survival in patients with non-Luminal A HR+ metastatic breast cancer using Blueprint and MammaPrint gene expression profiling tests.
  • I-SPY2 Trial NetworkcoreStrategic or Co-development PartnerAdaptive platform trial employing master framework allowing multiple treatments to be studied in parallel. Agendia contributes genomic profiling to guide treatment evaluation.
  • EORTC (European Organization for Research and Treatment of Cancer)coreStrategic or Co-development PartnerSponsor of MINDACT Phase III trial demonstrating MammaPrint's ability to safely de-escalate chemotherapy in clinically high-risk, MammaPrint Low Risk early-stage breast cancer patients.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Agendia competitors and assessment

Company assessment

Direct peers

  • Exact Sciences: Owner of the Oncotype DX Breast Recurrence Score test, the leading genomic assay for early-stage breast cancer treatment planning. Most direct competitor to MammaPrint, with broader indication coverage and substantially larger commercial scale.
  • NanoString Technologies: Developer of the Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50-based), a direct competitor providing breast cancer subtype and recurrence risk classification from FFPE tissue. Competes head-to-head with MammaPrint/BluePrint in the same indication.

Broad incumbents

  • Veracyte: Genomic diagnostics company spanning multiple indications (urology, thyroid, breast) including Prosigna-related assets and broader oncology decision-support. Larger and more diversified than Agendia, with overlapping breast cancer genomic testing.
  • Myriad Genetics: Established molecular diagnostics company with oncology and women's health testing (including BRACAnalysis and risk-of-recurrence assays). Larger scale and broader indication footprint, with overlapping oncology sales channels and shared leadership pedigree with Agendia (Agendia's CCO previously at Myriad).
  • NeoGenomics: Oncology-focused clinical laboratory services company offering comprehensive cancer genomic profiling across solid tumors. Serves similar hospital and oncologist customers and overlaps with Agendia on certain oncology biomarker testing.
  • Caris Life Sciences: Provider of comprehensive molecular profiling services (MI Profile, Caris Assure) used by oncologists for therapy selection. Comparable in serving oncologists with tumor profiling data, with a much broader indication footprint than Agendia.
  • Tempus AI: AI-enabled precision medicine platform offering multi-modal molecular profiling (DNA, RNA, imaging) for oncology. Competes for the same oncologist decision-support wallet with broader data and analytics capabilities than Agendia.
  • Hologic: Women's health diagnostics leader (including breast cancer screening and biopsy systems). Adjacent rather than directly competitive, but operates in the same breast cancer diagnostic workflow and could be a strategic acquirer of genomic testing assets.

Emerging players

  • Guardant Health: Liquid biopsy leader (Guardant360, Guardant Reveal) expanding into breast cancer minimal residual disease and treatment monitoring. Represents the emerging blood-based alternative that could pressure Agendia's tissue-based testing model over time.
  • Natera: Cell-free DNA testing company (Signatera) with growing presence in MRD and breast cancer recurrence monitoring. Represents the emerging blood-based competitive threat to Agendia's tissue-based recurrence risk testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Agendia social profiles

Digital presence

Agendia compliance and trust

Trust signal

Compliance3 records

Agendia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Agendia leadership team

Management profile

Number of profiles

Profiles19 records

Agendia funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Agendia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agendia

What does Agendia do?

Agendia provides clinical genomic diagnostic testing services for early-stage breast cancer, anchored by its MammaPrint 70-gene recurrence risk test and BluePrint 80-gene molecular subtyping test. Both tests are run from a single tumor tissue sample in Agendia's CLIA-regulated, CAP-accredited laboratories and produce combined results within 6 business days to help oncologists, surgeons, and pathologists personalize treatment decisions including chemotherapy benefit, endocrine therapy planning, and identification of aggressive tumor subtypes.

Is Agendia a public or private company?

Agendia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Agendia founded?

Agendia was founded in 2003. It employs 101 to 250 people.

Where is Agendia based?

Agendia is headquartered in Irvine, United States, in the North America region.

How does Agendia make money?

Two revenue lines are on record. MammaPrint Test is the primary driver. The others are bluePrint Test.

Who are Agendia's main competitors?

Direct peers on record are Exact Sciences and NanoString Technologies. Broad incumbents are Veracyte, Myriad Genetics, NeoGenomics, Caris Life Sciences, Tempus AI and Hologic. Emerging players are Guardant Health and Natera.

Does Agendia have an API?

No public API is recorded for Agendia.

What industry is Agendia in?

Agendia's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAKAFAJ, Breast Oncology, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LelezardAgendia annonce la validation clinique d'une approche de pathologie numérique alimentée par l'IAAgendia presented at ESMO 2026 a deep-learning algorithm that predicts MammaPrint recurrence risk from whole-slide images. The model, trained on 70,000 images, showed strong concordance (r=0.954) and classified 49% as high risk, with 10-year breast cancer-specific survival of 98.1% for low-risk versus 86.7% for high-risk.The future of tradingAgendia AI Assay Shows High Concordance With MammaPrint in Breast Cancer StudyAgendia announced clinical validation of an AI-driven digital pathology assay for breast cancer recurrence risk, with results presented at ESMO Congress 2026. The validation involved 372 early-stage patients in the RASTER study with median follow-up of 10.3 years, showing strong agreement with MammaPrint. Low-risk patients had better survival, and the assay outperformed clinical factors.Business Wire BlogAgendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 2026Agendia will present new research on AI-driven digital pathology for MammaPrint at ESMO 2026 in Madrid, including a podium presentation and two posters. The posters draw on the FLEX Study, which has enrolled over 25,000 patients, to examine genomic risk and biomarkers like Ki67 and BRCA mutations.Business Wire BlogAgendia Announces Definitive Mandatory Swiss Health Insurance Reimbursement for MammaPrintSwitzerland's FOPH granted definitive mandatory health insurance coverage for MammaPrint and other multigene expression tests, effective 1 July 2026. The ruling follows a Health Technology Assessment confirming MammaPrint's clinical efficacy and cost-effectiveness. Eligibility requires estrogen receptor-positive, HER2-negative tumors with up to three lymph nodes.PrecisionmedicineonlineAgendia's MammaPrint Can Inform Use of Aggressive Chemo in High-Risk Early Breast Cancer, Study ShowsA study of over 1,200 patients found MammaPrint can guide anthracycline use in high-risk early breast cancer. High-risk 2 patients with anthracycline had 100% three-year invasive disease-free survival versus 94.8% without, while high-risk 1 showed no benefit. Agendia is exploring MammaPrint's predictive value for immunotherapy.BioSpaceGenomic Profiling With MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast CancerAgendia published FLEX Study data showing MammaPrint High Risk 2 patients gain 3-year invasive disease-free survival benefit from anthracycline-based chemotherapy, while High Risk 1 patients show no benefit. The study included 1,259 patients with a median follow-up of 3.2 years, and findings led to an NCCN guideline update.Business Wire BlogGenomic Profiling With MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast CancerA study of 1,259 patients in the FLEX Study found that MammaPrint High Risk 2 tumors showed improved 3-year invasive disease-free survival with anthracycline-based chemotherapy versus taxane-cyclophosphamide, while High Risk 1 tumors showed no benefit. The findings led to an update in NCCN guidelines recognizing MammaPrint as the only genomic test to guide anthracycline use in this population.BioSpaceAgendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast CancerAgendia will present two FLEX study posters at ASCO 2026, one on MammaPrint High Risk 2 tumors showing higher homologous recombination deficiency scores, and another on integrating BluePrint and ImPrint to predict pathologic complete response in HER2+ breast cancer. The data supports NCCN guidelines recognizing MammaPrint for anthracycline use.BioSpaceAgendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast CancerAgendia will present FLEX Study data at ASBrS 2026 showing MammaPrint + BluePrint perform consistently across self-reported race in genomically basal-type breast cancer. In 451 patients, 46% achieved pathologic complete response, driven by MammaPrint index, age, and platinum-based chemotherapy rather than race. The findings support biology-driven treatment decisions.Business Wire BlogAgendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast CancerAgendia will present new FLEX study data at ASBrS 2026, showing MammaPrint + BluePrint perform consistently across self-reported race in genomically basal-type breast cancer patients. In 451 patients, 46% achieved pathologic complete response, with pCR driven by MammaPrint index, age, and platinum-based chemotherapy rather than race.